News

News

OCT

The first randomized trial to examine serial optical coherence tomography (OCT) in primary percutaneous coronary intervention (PCI) was reported at the Transcatheter Cardiovascular Therapeutics (...

St. Jude Medical CE mark Tendril STS IsoFlex Optim MRI Scans

St. Jude Medical Inc. announced CE mark approval of updated labeling for its Tendril STS and IsoFlex Optim pacing leads, allowing existing and future patients with the devices access to ...

IVUS, CTOs

A new study found that intravascular ultrasound (IVUS)-guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided...

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided...

A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting stents (DP-SES) found that the...

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that the procedure combined with...

FEI released RemoteViz for Open Inventor, a software development framework for interactive remote 2-D and 3-D visualization.

Svelte Coronary DES DIRECT II Trial Six Month Results TCT 2014

Svelte Medical Systems reported that its drug-eluting coronary stent Integrated Delivery System (IDS) for percutaneous coronary intervention (PCI) met all DIRECT II study six-month angiographic...

Mallinckrodt U.S. Launch OptiSync Contrast Data Management System

Mallinckrodt announced the U.S. launch of the OptiSync data management system as a new technology in its Global Medical Imaging segment. 

September 24, 2014 — An initiative to improve the use of cardiac telemetry at Christiana Care Health System enhanced the value of care to patients and resulted in savings of $4.8 million,...

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated...

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb...

Capricor ALLSTAR Phase I Clinical Trial TCT 2014 Stem Cells Myocardial Regenerat

Capricor Therapeutics Inc. presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation...

September 24, 2014 — GE Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Discovery IQ PET/CT (positron emission tomography/computed tomography) system.

New analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial...

Two-Year Results CoreValve U.S. Pivotal Trial TCT 2014

In extended follow-up from the CoreValve U.S. Pivotal Trial, the self-expanding transcatheter aortic valve was shown to have low rates of all-cause mortality and major stroke. Findings were...

September 22, 2014 — A first-of-its kind study found that using a cerebral protection device during transcatheter aortic valve replacement (TAVR) can significantly reduce the number and volume of...

September 22, 2014 — According to a new study, while it is common for patients who have migraine to have a patent foramen ovale, a procedure to repair this heart defect does not significantly...

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said: “Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly...

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to...